Home›Rheumatology› Immune signaling and bidirectional neuropeptide release drive nociceptor sensitization in osteoarthritis pain
Immune signaling and bidirectional neuropeptide release drive nociceptor sensitization in osteoarthritis painImmune Signaling and Nerve Activity Drive Osteoarthritis Pain
Frontiers in MedicinePublished September 3, 2026Study authors: Zhongyan Mao, Kang Wang, Yanxuan Wu, Gongchang Yu, Bin ShiDOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Recognize that immune-mediated nociceptor sensitization and bidirectional neuropeptide signaling drive osteoarthritis pain.
This mini review explores the complex interplay between immune signaling and nociceptor activity in osteoarthritis. The authors synthesize how various cells, including activated macrophages, fibroblast-like synoviocytes, mast cells, T cells, and damaged chondrocytes, contribute to nociceptor sensitization. This process is mediated by cytokines, chemokines, prostaglandins, nerve growth factor, complement fragments, and damage-associated molecular patterns.
Furthermore, the review details how these factors lower nociceptor thresholds and alter the activity of TRP, Piezo, and voltage-gated sodium channels. A bidirectional amplification circuit is also described, where sensory neurons release neuropeptides that influence vascular permeability and immune-cell behavior. While persistent peripheral input may recruit dorsal root ganglion macrophages and activate spinal microglia and astrocytes, the authors note that direct evidence for specific central immune mechanisms in human osteoarthritis is limited.
Clinically, these mechanisms suggest that identifying specific components of pain—inflammatory, structural, and nociplastic—could guide targeted therapies. Potential strategies include combining local immune modulation with neural targeting. However, the limited evidence regarding central immune mechanisms in humans necessitates caution when interpreting the full extent of central nervous system involvement in the condition.
How this fits prior evidence
This review addresses a gap in the understanding of the underlying mechanisms of pain in osteoarthritis. It expands upon the role of inflammaging and immunosenescence as central to osteoarthritis pathogenesis by detailing the specific cellular and molecular drivers of nociceptor sensitization. While it does not directly relate to the efficacy of icariin or the use of extracellular vesicles, it provides a mechanistic framework for why local immune modulation and neural targeting may be necessary to address the complex pain profile of the condition.
Researchers have identified how the body creates pain in people with osteoarthritis. The study explains that inflammation in the joint involves several types of cells, including macrophages and T cells. These cells release chemicals like cytokines and prostaglandins that sensitize the nerves in the area. This process makes it easier for the body to send pain signals to the brain.
In addition to local inflammation, the study describes a bidirectional circuit. This means that while immune cells can activate nerves, the nerves themselves can also release neuropeptides. These neuropeptides can then affect blood vessels and the behavior of immune cells. This cycle can create a loop that keeps the pain active.
While the research shows these complex interactions, it is important to note that evidence for certain central immune mechanisms in humans is currently limited. These findings may eventually help doctors better distinguish between different types of pain and choose more specific treatments for patients.
What this means for you:
Osteoarthritis pain involves a complex loop between immune cell activity and nerve signals in the joint.
Common questions
How do immune cells cause pain in osteoarthritis?
Immune cells like macrophages and T cells release chemicals such as cytokines and prostaglandins. These substances sensitize the nerves in the joint. This makes the nerves more reactive, which contributes to the sensation of pain in people with osteoarthritis.
Is there a cycle that makes the pain worse?
Yes, there is a bidirectional circuit. While immune cells can activate nerves, the sensory neurons can also release neuropeptides. These neuropeptides can then affect blood vessels and the behavior of immune cells, potentially creating a loop that maintains the pain.
What are the limitations of this research?
While the study identifies many ways that immune cells and nerves interact, there is currently limited direct evidence regarding specific central immune mechanisms in humans with osteoarthritis. More research is needed to fully understand these specific central processes.
Pain in osteoarthritis (OA) is not explained adequately by cartilage loss or radiographic severity. Synovial inflammation, tissue damage, and neural plasticity interact across the joint, dorsal root ganglia, spinal cord, and brain to shape the intensity and persistence of symptoms. This mini review examines the synovium as an immune niche in OA pain and follows the signals that connect activated macrophages, fibroblast-like synoviocytes, mast cells, T cells, and damaged chondrocytes with nociceptor sensitization. Cytokines, chemokines, prostaglandins, nerve growth factor, complement fragments, and damage-associated molecular patterns can lower nociceptor thresholds and alter TRP, Piezo, and voltage-gated sodium channel activity. Sensory neurons, in turn, release neuropeptides that affect vascular permeability and immune-cell behavior, creating a bidirectional amplification circuit. Persistent peripheral input may recruit dorsal root ganglion macrophages and activate spinal microglia and astrocytes, although direct evidence for specific central immune mechanisms in human OA remains limited. Therapeutic translation therefore requires more than generalized anti-inflammatory treatment. Mechanism-informed stratification integrating synovitis imaging, soluble biomarkers, quantitative sensory testing, and clinical pain features may help distinguish inflammatory, structural, and nociplastic contributions and guide rational combinations of local immune modulation and neural targeting.
